Wildagliptyna – wyjątkowy inhibitor DPP-4 Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 22, 2022
Słowa kluczowe:
wildagliptyna, inhibitor DPP-4, inkretyny, cukrzyca typu 2, terapia skojarzona
##plugins.themes.bootstrap3.article.main##
Abstrakt
Wildagliptyna jest jedynym lekiem z grupy inhibitorów DPP-4, który stosuje się 2 razy dziennie. Chociaż nie przeprowadzono badania poświęconego bezpieczeństwu sercowo-naczyniowemu stosowania tego leku, to licznie opublikowane metaanalizy oraz badania obserwacyjne jednoznacznie potwierdziły bezpieczeństwo wildagliptyny w tym zakresie. Szczególną uwagę zwraca badanie VERIFY, które wykazało, że zastosowanie skojarzonego leczenia metforminą i wildagliptyną od momentu rozpoznania cukrzycy typu 2 zapewnia długotrwałą skuteczność i odkłada w czasie potrzebę wdrożenia insulinoterapii.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Dzida , G. (2022). Wildagliptyna – wyjątkowy inhibitor DPP-4 . Medycyna Faktów , 15(4(57), 394-396. https://doi.org/10.24292/01.MF.0422.2
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Golightly LK, Drayna CC , McDermott MT. Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors. Clin Pharmacokinet. 2012; 51: 501-14. http://doi.org/10.1007/BF03261927.
2. Ou SM, Shih CJ , Chao PW et al. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med. 2015; 163: 663-72. http://doi.org/10.7326/M15-0308.
3. Kaneko M, Narukawa M. Meta-Analysis of Dipeptidyl Peptidase-4 Inhibitors Use and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. Diabetes Res Clin Pract. 2016; 116: 171-82. http://doi.org/10.1016/j.diabres.2016.04.012.
4. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S et al. 2022 Guidelines on the Management of Patients with Diabetes. APosition of Diabetes Poland. Curr Top Diabetes. 2022; 2: 1-134.
5. Matthews D, Del Prato S, Mohan V et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020; 11(11): 2465- 2476. https://doi.org/10. 1007/s13300-020-00926-7.
6. Matthews DR, Paldánius PM, Proot P et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208): 1519-1529. https://doi.org/10.1016/S0140-6736(19)32131-2.
7. Chan JCN, Paldánius PM, Mathieu C et al. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab. 2021; 23(1): 245-251. https://doi.org/10.1111/dom.14192.
8. Davies MJ, Aroda VR, Collins BS et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA ) and the European Association for the Study of Diabetes (EASD). D iabetologia. 2022; 65: 1925-1966. https://doi.org/10.1007/s00125-022-05787-2.
2. Ou SM, Shih CJ , Chao PW et al. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ann Intern Med. 2015; 163: 663-72. http://doi.org/10.7326/M15-0308.
3. Kaneko M, Narukawa M. Meta-Analysis of Dipeptidyl Peptidase-4 Inhibitors Use and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. Diabetes Res Clin Pract. 2016; 116: 171-82. http://doi.org/10.1016/j.diabres.2016.04.012.
4. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S et al. 2022 Guidelines on the Management of Patients with Diabetes. APosition of Diabetes Poland. Curr Top Diabetes. 2022; 2: 1-134.
5. Matthews D, Del Prato S, Mohan V et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020; 11(11): 2465- 2476. https://doi.org/10. 1007/s13300-020-00926-7.
6. Matthews DR, Paldánius PM, Proot P et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208): 1519-1529. https://doi.org/10.1016/S0140-6736(19)32131-2.
7. Chan JCN, Paldánius PM, Mathieu C et al. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab. 2021; 23(1): 245-251. https://doi.org/10.1111/dom.14192.
8. Davies MJ, Aroda VR, Collins BS et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA ) and the European Association for the Study of Diabetes (EASD). D iabetologia. 2022; 65: 1925-1966. https://doi.org/10.1007/s00125-022-05787-2.